Evaluation of corticoresistance in patients with thyroid eye disease and use of rituximab as a second-line treatment
CAS ≥ 2, after first-line treatment, could be used as a corticoresistance marker. Corticoresistant patients should be subject to long-term follow-up for early detection of reactivation to reduce the delay to second-line treatment. Rituximab is a well-tolerated choice of second-line treatment and has a long-lasting effect on disease activity. Although TSI is a valuable biomarker of Graves' disease and TED activity, according to our results, TSI cannot be used as a marker of corticoresistance.
Authors
- Martin Radvanský (ORCID: https://orcid.org/0000-0002-8421-7658)
- David Karásek (ORCID: https://orcid.org/0000-0002-9309-4952)
- Marta Karhanová (ORCID: https://orcid.org/0000-0002-0879-3055)
- Jan Schovánek (ORCID: https://orcid.org/0000-0002-5776-6766)
- Roman Dohnal
- Klara Pekarova
Institutions
- VSB - Technical University of Ostrava (CZ)
- University Hospital Olomouc (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Endocrine
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1007/s12020-024-04108-4
- Citations
- 3
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Ministerstvo Zdravotnictví Ceské Republiky
- Univerzita Palackého v Olomouci